Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025556 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Phase 2 study of Episodic Migraine Headache, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
- 20
- Study locations
NCT02025556 is a Phase 2 study of Episodic Migraine Headache that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 297 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT02025556, a Phase 2 study of Episodic Migraine Headache, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LBR-101 High Dose
- DRUG LBR-101 Low Dose
Study Locations (20)
California
- Teva Investigational Site 161 - Anaheim
- Teva Investigational Site 116 - Fullerton
- Teva Investigational Site 119 - Long Beach
- Teva Investigational Site 146 - Oceanside
- Teva Investigational Site 113 - San Francisco
- Teva Investigational Site 108 - Stanford
- Teva Investigational Site 112 - Walnut Creek
Florida
- Teva Investigational Site 143 - DeLand
- Teva Investigational Site 137 - Hialeah
- Teva Investigational Site 159 - Hollywood
- Teva Investigational Site 101 - Jacksonville
- Teva Investigational Site 166 - Jacksonville
- Teva Investigational Site 129 - Maitland
- Teva Investigational Site 167 - Orlando
Arizona
- Teva Investigational Site 145 - Gilbert
- Teva Investigational Site 130 - Phoenix
- Teva Investigational Site 117 - Scottsdale
Arkansas
- Teva Investigational Site 158 - Little Rock
Colorado
- Teva Investigational Site 132 - Boulder
Connecticut
- Teva Investigational Site 162 - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2015-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025556
The ClinicalTrials.gov registry entry for NCT02025556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Episodic Migraine Headache appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02025556 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02025556 about?
NCT02025556 is a clinical study titled "A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine". The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
What is the current status of trial NCT02025556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2014-01-31. Estimated completion is 2015-03-31.
What conditions does trial NCT02025556 study?
This clinical trial studies the following conditions: Episodic Migraine Headache.
What interventions are being tested in trial NCT02025556?
The interventions under investigation include: Placebo (DRUG), LBR-101 High Dose (DRUG), LBR-101 Low Dose (DRUG).
Who is sponsoring clinical trial NCT02025556?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02025556 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.